Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CBIO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
N/A
Current
Estimates
Q2.23
N/A
NA
vs NA
Q3.23
N/A
NA
vs NA
Q4.23
N/A
NA
vs NA
Q1.24
N/A
NA
vs NA
Q2.24
N/A
NA
vs NA
Q3.24
N/A
NA
vs NA
Q4.24
N/A
NA
vs NA
Q1.25
N/A
NA
vs NA
Q2.25
N/A
NA
vs NA
Q3.25
N/A
NA
vs NA
Sales Growth
N/A
Current
Estimates
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Q3.25
NA
NA vs NA
Return on Equity
N/A
Q2.23
NA
NA
vs NA
Q3.23
NA
NA
vs NA
Q4.23
NA
NA
vs NA
Q1.24
NA
NA
vs NA
Q2.24
NA
NA
vs NA
Q3.24
NA
NA
vs NA
Q4.24
NA
NA
vs NA
Q1.25
NA
NA
vs NA
Q2.25
NA
NA
vs NA
Q3.25
NA
NA
vs NA
Institutionnal Ownership
QoQ
Q3.22
34
34
vs 40
-15%
Q4.22
36
36
vs 34
6%
Q1.23
37
37
vs 36
3%
Q2.23
29
29
vs 37
-22%
Q3.23
32
32
vs 29
10%
Q4.23
1
1
vs 32
-97%
Q1.24
NA
NA
vs NA
NA
Q2.24
NA
NA
vs NA
NA
Q3.24
NA
NA
vs NA
NA
Q4.24
1
1
vs NA
NA
N/A
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
seekingalpha.com
11 hours ago
Quote Panel
Key Metrics
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
NASDAQ
Relative Strenght
100
Volume Buzz
433%
Earning Acce
No
Dist 52w H.
78%Relative Strength
CBIO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
2026-Revenue
80%2026-EPS
29%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
Wedbush
initialisePrevious: Not converted
2025-07-14
Now: Outperform
